Brefel-Courbon C - Search Results

1

The pharmacologic treatment of gait ignition failure.

Rascol O, Fabre N, Brefel-Courbon C, Montastruc JL. Rascol O, et al. Adv Neurol. 2001;87:255-64. Adv Neurol. 2001. PMID: 11347230 Review. No abstract available.

2

[Parkinson "plus"].

Fabre N, Brefel-Courbon C, Rascol O. Fabre N, et al. Rev Prat. 1997 May 15;47(10):1077-82. Rev Prat. 1997. PMID: 9208670 French.

3

Central cardiovascular effects of tacrine in the conscious dog: a role for catecholamines and vasopressin release.

Allal C, Lazartigues E, Tran MA, Brefel-Courbon C, Gharib C, Montastruc JL, Rascol O. Allal C, et al. Eur J Pharmacol. 1998 May 8;348(2-3):191-8. doi: 10.1016/s0014-2999(98)00143-5. Eur J Pharmacol. 1998. PMID: 9652334

4

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.

Rascol O, Sieradzan K, Peyro-Saint-Paul H, Thalamas C, Brefel-Courbon C, Senard JM, Ladure P, Montastruc JL, Lees A. Rascol O, et al. Mov Disord. 1998 Jul;13(4):673-6. doi: 10.1002/mds.870130411. Mov Disord. 1998. PMID: 9686773 Clinical Trial.

5

Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study.

Montastruc JL, Pelat M, Verwaerde P, Brefel-Courbon C, Tran MA, Blin O, Rascol O, Senard JM. Montastruc JL, et al. Fundam Clin Pharmacol. 1998;12(4):398-402. doi: 10.1111/j.1472-8206.1998.tb00963.x. Fundam Clin Pharmacol. 1998. PMID: 9711461 Clinical Trial.

6

[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].

Rascol O, Brefel-Courbon C, Blin O. Rascol O, et al. Therapie. 1998 Jan-Feb;53(1):43-8. Therapie. 1998. PMID: 9773099 French.

7

Endogenous central cholinergic systems and baroreflex modulation in the conscious dog.

Lazartigues E, Tran MA, Brefel-Courbon C, Montastruc JL, Rascol O. Lazartigues E, et al. Fundam Clin Pharmacol. 1998;12(6):643-5. doi: 10.1111/j.1472-8206.1998.tb00999.x. Fundam Clin Pharmacol. 1998. PMID: 9818298

8

Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat.

Lazartigues E, Freslon JL, Tellioglu T, Brefel-Courbon C, Pelat M, Tran MA, Montastruc JL, Rascol O. Lazartigues E, et al. Eur J Pharmacol. 1998 Nov 13;361(1):61-71. doi: 10.1016/s0014-2999(98)00717-1. Eur J Pharmacol. 1998. PMID: 9851542

9

Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.

Rascol O, Brefel-Courbon C, Descombes S, Montastruc JL. Rascol O, et al. Adv Neurol. 1999;80:485-90. Adv Neurol. 1999. PMID: 10410760 Review. No abstract available.

10

Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.

Thalamas C, Taylor A, Brefel-Courbon C, Eagle S, Fitzpatrick K, Rascol O. Thalamas C, et al. Eur J Clin Pharmacol. 1999 Jun;55(4):299-303. doi: 10.1007/s002280050632. Eur J Clin Pharmacol. 1999. PMID: 10424323 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters